WO2000010573A1 - Compounds, compositions and methods for treating or preventing viral infections and associated diseases - Google Patents
Compounds, compositions and methods for treating or preventing viral infections and associated diseases Download PDFInfo
- Publication number
- WO2000010573A1 WO2000010573A1 PCT/US1999/018785 US9918785W WO0010573A1 WO 2000010573 A1 WO2000010573 A1 WO 2000010573A1 US 9918785 W US9918785 W US 9918785W WO 0010573 A1 WO0010573 A1 WO 0010573A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- radical
- furan
- unsubstituted
- oxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 139
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 36
- 201000010099 disease Diseases 0.000 title claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 17
- 230000009385 viral infection Effects 0.000 title claims description 15
- 208000036142 Viral infection Diseases 0.000 title claims description 14
- -1 rhodanine benzoic acids Chemical class 0.000 claims abstract description 256
- 241000700605 Viruses Species 0.000 claims abstract description 33
- 208000015181 infectious disease Diseases 0.000 claims abstract description 18
- 241000710781 Flaviviridae Species 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 14
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 144
- 150000003254 radicals Chemical class 0.000 claims description 137
- 125000004432 carbon atom Chemical group C* 0.000 claims description 93
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 86
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 83
- 229910052739 hydrogen Inorganic materials 0.000 claims description 79
- 239000001257 hydrogen Substances 0.000 claims description 79
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 68
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 66
- 125000000217 alkyl group Chemical group 0.000 claims description 66
- 229910052736 halogen Inorganic materials 0.000 claims description 66
- 150000002367 halogens Chemical class 0.000 claims description 66
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 61
- 125000003545 alkoxy group Chemical group 0.000 claims description 58
- 229920006395 saturated elastomer Polymers 0.000 claims description 56
- 125000001931 aliphatic group Chemical group 0.000 claims description 53
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 49
- 229910052760 oxygen Inorganic materials 0.000 claims description 48
- 229910052717 sulfur Inorganic materials 0.000 claims description 48
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 44
- 125000001424 substituent group Chemical group 0.000 claims description 44
- 125000004423 acyloxy group Chemical group 0.000 claims description 41
- 229930192474 thiophene Natural products 0.000 claims description 41
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 39
- 125000004414 alkyl thio group Chemical group 0.000 claims description 38
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 36
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 36
- 125000003282 alkyl amino group Chemical group 0.000 claims description 36
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 36
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 36
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 35
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 35
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 35
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 35
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 35
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 34
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 34
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 34
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 34
- 150000003852 triazoles Chemical class 0.000 claims description 34
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 33
- WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical compound C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 claims description 32
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 32
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 32
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 32
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 32
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 32
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 32
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 32
- 150000003536 tetrazoles Chemical class 0.000 claims description 32
- 125000005518 carboxamido group Chemical group 0.000 claims description 31
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 31
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 30
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 28
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims description 28
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 27
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 125000003367 polycyclic group Chemical group 0.000 claims description 25
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 24
- 239000003443 antiviral agent Substances 0.000 claims description 22
- 235000019260 propionic acid Nutrition 0.000 claims description 21
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000002252 acyl group Chemical group 0.000 claims description 20
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 20
- 125000002071 phenylalkoxy group Chemical group 0.000 claims description 20
- 239000002243 precursor Substances 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 claims description 16
- GDAXJBDYNVDMDF-UHFFFAOYSA-N 1,2,4-benzotriazine Chemical compound N1=NC=NC2=CC=CC=C21 GDAXJBDYNVDMDF-UHFFFAOYSA-N 0.000 claims description 16
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 16
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 16
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 16
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 claims description 16
- LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 claims description 16
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 16
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 16
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 16
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 16
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 16
- 239000011593 sulfur Substances 0.000 claims description 16
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 15
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 15
- 241000711557 Hepacivirus Species 0.000 claims description 14
- 239000004305 biphenyl Substances 0.000 claims description 14
- 235000010290 biphenyl Nutrition 0.000 claims description 14
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 14
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 claims description 13
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 13
- 125000004982 dihaloalkyl group Chemical group 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 9
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical group C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 8
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 8
- 150000002430 hydrocarbons Chemical group 0.000 claims description 7
- 125000005647 linker group Chemical group 0.000 claims description 7
- 125000006682 monohaloalkyl group Chemical group 0.000 claims description 7
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 7
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 7
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 7
- 241000710831 Flavivirus Species 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 241000710778 Pestivirus Species 0.000 claims description 6
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- FXBAZEDVRCUTAU-UHFFFAOYSA-N 4-[5-[[5-(1-benzofuran-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2OC3=CC=CC=C3C=2)O1 FXBAZEDVRCUTAU-UHFFFAOYSA-N 0.000 claims description 5
- ILGGXVMASBVOQH-UHFFFAOYSA-N 4-[5-[[5-[2-chloro-5-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)O1 ILGGXVMASBVOQH-UHFFFAOYSA-N 0.000 claims description 5
- VOKFQQYBDPILQK-UHFFFAOYSA-N 4-[5-[[5-[3,5-bis(trifluoromethyl)phenyl]furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)O1 VOKFQQYBDPILQK-UHFFFAOYSA-N 0.000 claims description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 5
- 150000003857 carboxamides Chemical class 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 229960000329 ribavirin Drugs 0.000 claims description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 5
- 229940124530 sulfonamide Drugs 0.000 claims description 5
- 150000003456 sulfonamides Chemical class 0.000 claims description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- ANYINBWJHFDPCF-UHFFFAOYSA-N 4-[5-[[5-(1-benzothiophen-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2SC3=CC=CC=C3C=2)O1 ANYINBWJHFDPCF-UHFFFAOYSA-N 0.000 claims description 4
- ZWKXQSFYEBAYEP-UHFFFAOYSA-N 4-[5-[[5-(5-bromo-2-methoxyphenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound COC1=CC=C(Br)C=C1C(O1)=CC=C1C=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)C(=S)S1 ZWKXQSFYEBAYEP-UHFFFAOYSA-N 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 125000002723 alicyclic group Chemical group 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000002924 anti-infective effect Effects 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 229940121357 antivirals Drugs 0.000 claims description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 239000012678 infectious agent Substances 0.000 claims description 4
- 229940047124 interferons Drugs 0.000 claims description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
- IRNIRFQMWORVLH-UHFFFAOYSA-N 2-[5-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid Chemical compound O=C1N(CC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=C(Cl)C(Cl)=CC=2)O1 IRNIRFQMWORVLH-UHFFFAOYSA-N 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- HERNJLYVVFINQH-UHFFFAOYSA-N 3-[4-oxo-2-sulfanylidene-5-[(5-thiophen-2-ylthiophen-2-yl)methylidene]-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2SC=CC=2)S1 HERNJLYVVFINQH-UHFFFAOYSA-N 0.000 claims description 3
- OTUNDPZQJSLSPW-UHFFFAOYSA-N 3-[4-oxo-5-[[5-(2-phenylethynyl)thiophen-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C#CC=2C=CC=CC=2)S1 OTUNDPZQJSLSPW-UHFFFAOYSA-N 0.000 claims description 3
- BNNJRWDHJHFLIJ-UHFFFAOYSA-N 3-[5-[[5-(1-benzofuran-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2OC3=CC=CC=C3C=2)O1 BNNJRWDHJHFLIJ-UHFFFAOYSA-N 0.000 claims description 3
- JIBSYMDTKWSGDS-UHFFFAOYSA-N 3-[5-[[5-(1-benzothiophen-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2SC3=CC=CC=C3C=2)O1 JIBSYMDTKWSGDS-UHFFFAOYSA-N 0.000 claims description 3
- RXVQGIXCWXKRCJ-UHFFFAOYSA-N 3-[5-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=C(Cl)C=CC=2)O1 RXVQGIXCWXKRCJ-UHFFFAOYSA-N 0.000 claims description 3
- ZDJIYYZZVFPMMY-UHFFFAOYSA-N 3-[5-[[5-(5-chlorothiophen-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2SC(Cl)=CC=2)O1 ZDJIYYZZVFPMMY-UHFFFAOYSA-N 0.000 claims description 3
- RFLOFTCFNZOEEX-UHFFFAOYSA-N 3-[5-[[5-(5-methylpyridin-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound N1=CC(C)=CC=C1C(O1)=CC=C1C=C1C(=O)N(CCC(O)=O)C(=S)S1 RFLOFTCFNZOEEX-UHFFFAOYSA-N 0.000 claims description 3
- LTKIFHONEMVJKE-UHFFFAOYSA-N 3-[5-[[5-[3,5-bis(trifluoromethyl)phenyl]furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)O1 LTKIFHONEMVJKE-UHFFFAOYSA-N 0.000 claims description 3
- CLNJVHJDWANXRD-UHFFFAOYSA-N 4-[5-[[5-(5-methylpyridin-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound N1=CC(C)=CC=C1C(O1)=CC=C1C=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)C(=S)S1 CLNJVHJDWANXRD-UHFFFAOYSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- BCJWNIPBRIIUMA-UHFFFAOYSA-N 2-[5-[[5-(3,4-dichlorophenyl)thiophen-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid Chemical compound O=C1N(CC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=C(Cl)C(Cl)=CC=2)S1 BCJWNIPBRIIUMA-UHFFFAOYSA-N 0.000 claims description 2
- MLJZUYRFSYEQSB-UHFFFAOYSA-N 2-[5-[[5-(5-chlorothiophen-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(C(C)C(O)=O)C(=S)SC1=CC1=CC=C(C=2SC(Cl)=CC=2)O1 MLJZUYRFSYEQSB-UHFFFAOYSA-N 0.000 claims description 2
- MPRBSTSVHCQTLS-UHFFFAOYSA-N 2-[5-[[5-[2-(3-tert-butylphenoxy)phenyl]furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid Chemical compound CC(C)(C)C1=CC=CC(OC=2C(=CC=CC=2)C=2OC(C=C3C(N(CC(O)=O)C(=S)S3)=O)=CC=2)=C1 MPRBSTSVHCQTLS-UHFFFAOYSA-N 0.000 claims description 2
- DCKNCBINJDHCQH-UHFFFAOYSA-N 2-[5-[[5-[2-chloro-5-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid Chemical compound O=C1N(CC(=O)O)C(=S)SC1=CC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)O1 DCKNCBINJDHCQH-UHFFFAOYSA-N 0.000 claims description 2
- UIFOOGQWHRZMSS-UHFFFAOYSA-N 2-[5-[[5-[2-chloro-5-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(C(C)C(O)=O)C(=S)SC1=CC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)O1 UIFOOGQWHRZMSS-UHFFFAOYSA-N 0.000 claims description 2
- DWYCOQIBWGDNTB-UHFFFAOYSA-N 3-[4-oxo-2-sulfanylidene-5-[[5-[2-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2C(=CC=CC=2)C(F)(F)F)O1 DWYCOQIBWGDNTB-UHFFFAOYSA-N 0.000 claims description 2
- LPPIJTLLYCREQK-UHFFFAOYSA-N 3-[4-oxo-5-[(5-phenanthren-9-ylfuran-2-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2C3=CC=CC=C3C3=CC=CC=C3C=2)O1 LPPIJTLLYCREQK-UHFFFAOYSA-N 0.000 claims description 2
- NYCSYKPYBNUWSH-UHFFFAOYSA-N 3-[4-oxo-5-[(6-phenylmethoxy-1-benzofuran-2-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC(OC1=C2)=CC1=CC=C2OCC1=CC=CC=C1 NYCSYKPYBNUWSH-UHFFFAOYSA-N 0.000 claims description 2
- LJRJDXMSMUTDMG-UHFFFAOYSA-N 3-[4-oxo-5-[[4-(2-phenylethynyl)thiophen-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC(C#CC=2C=CC=CC=2)=CS1 LJRJDXMSMUTDMG-UHFFFAOYSA-N 0.000 claims description 2
- FTPQROBMRFRTKE-UHFFFAOYSA-N 3-[5-[[3-(4-bromophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=C(C=2C=CC(Br)=CC=2)C=CO1 FTPQROBMRFRTKE-UHFFFAOYSA-N 0.000 claims description 2
- UUGGJDRXWTZFPU-UHFFFAOYSA-N 3-[5-[[3-(4-carboxyphenyl)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C=C(C=CC=2)C(O)=O)O1 UUGGJDRXWTZFPU-UHFFFAOYSA-N 0.000 claims description 2
- AXCJOMPUQXLRHY-UHFFFAOYSA-N 3-[5-[[5-(1,3-benzodioxol-5-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=C3OCOC3=CC=2)O1 AXCJOMPUQXLRHY-UHFFFAOYSA-N 0.000 claims description 2
- DTQXRARCWDVOER-UHFFFAOYSA-N 3-[5-[[5-(1h-isoquinolin-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(N2C=CC3=CC=CC=C3C2)O1 DTQXRARCWDVOER-UHFFFAOYSA-N 0.000 claims description 2
- NNIWBABHLNDVQI-UHFFFAOYSA-N 3-[5-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=C(Cl)C(Cl)=CC=2)O1 NNIWBABHLNDVQI-UHFFFAOYSA-N 0.000 claims description 2
- VJRWEBRXOWCLBJ-UHFFFAOYSA-N 3-[5-[[5-(3,5-dimethylphenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound CC1=CC(C)=CC(C=2OC(C=C3C(N(CCC(O)=O)C(=S)S3)=O)=CC=2)=C1 VJRWEBRXOWCLBJ-UHFFFAOYSA-N 0.000 claims description 2
- YZLFZFALAZYTCI-UHFFFAOYSA-N 3-[5-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=CC(Cl)=CC=2)O1 YZLFZFALAZYTCI-UHFFFAOYSA-N 0.000 claims description 2
- JFZRISHMENACBJ-UHFFFAOYSA-N 3-[5-[[5-(9h-fluoren-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=C3C(C4=CC=CC=C4C3)=CC=2)O1 JFZRISHMENACBJ-UHFFFAOYSA-N 0.000 claims description 2
- FSLFLJUCXHIIIT-UHFFFAOYSA-N 3-[5-[[5-(furan-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2OC=CC=2)O1 FSLFLJUCXHIIIT-UHFFFAOYSA-N 0.000 claims description 2
- IMOXAQYIPWLETJ-UHFFFAOYSA-N 3-[5-[[5-[2-chloro-5-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)O1 IMOXAQYIPWLETJ-UHFFFAOYSA-N 0.000 claims description 2
- FIABXFGVKITLTD-UHFFFAOYSA-N 4-[4-oxo-2-sulfanylidene-5-[(5-thiophen-2-ylfuran-2-yl)methylidene]-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2SC=CC=2)O1 FIABXFGVKITLTD-UHFFFAOYSA-N 0.000 claims description 2
- UESHAGCAPQNKDV-UHFFFAOYSA-N 4-[4-oxo-2-sulfanylidene-5-[[5-(2,3,5,6-tetrafluoropyridin-4-yl)furan-2-yl]methylidene]-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C(=C(F)N=C(F)C=2F)F)O1 UESHAGCAPQNKDV-UHFFFAOYSA-N 0.000 claims description 2
- NFVQCLBMXZOTCH-UHFFFAOYSA-N 4-[4-oxo-2-sulfanylidene-5-[[5-[2-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C(=CC=CC=2)C(F)(F)F)O1 NFVQCLBMXZOTCH-UHFFFAOYSA-N 0.000 claims description 2
- QAHMUMQBHABRJN-UHFFFAOYSA-N 4-[4-oxo-5-[(5-phenylfuran-2-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C=CC=CC=2)O1 QAHMUMQBHABRJN-UHFFFAOYSA-N 0.000 claims description 2
- XYUOEKCDTLSEKK-UHFFFAOYSA-N 4-[4-oxo-5-[[5-(5-propylthiophen-2-yl)furan-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound S1C(CCC)=CC=C1C(O1)=CC=C1C=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)C(=S)S1 XYUOEKCDTLSEKK-UHFFFAOYSA-N 0.000 claims description 2
- LGCUWFNJRGQIAE-UHFFFAOYSA-N 4-[5-[(5-formylfuran-2-yl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=O)O1 LGCUWFNJRGQIAE-UHFFFAOYSA-N 0.000 claims description 2
- HOXMDINDDVBZAY-UHFFFAOYSA-N 4-[5-[[5-(1,3-benzodioxol-5-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C=C3OCOC3=CC=2)O1 HOXMDINDDVBZAY-UHFFFAOYSA-N 0.000 claims description 2
- CBSUFPYHZPIGQM-UHFFFAOYSA-N 4-[5-[[5-(1h-indol-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2NC3=CC=CC=C3C=2)O1 CBSUFPYHZPIGQM-UHFFFAOYSA-N 0.000 claims description 2
- DEVORSCVJQRCPL-UHFFFAOYSA-N 4-[5-[[5-(2,3-dichlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C(=C(Cl)C=CC=2)Cl)O1 DEVORSCVJQRCPL-UHFFFAOYSA-N 0.000 claims description 2
- JUEZGLZGJGJVQB-UHFFFAOYSA-N 4-[5-[[5-(2-chlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C(=CC=CC=2)Cl)O1 JUEZGLZGJGJVQB-UHFFFAOYSA-N 0.000 claims description 2
- RUNPFTNEWOAPPP-UHFFFAOYSA-N 4-[5-[[5-(3,4-difluorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C=C(F)C(F)=CC=2)O1 RUNPFTNEWOAPPP-UHFFFAOYSA-N 0.000 claims description 2
- PGLXDIOYDKBTCB-UHFFFAOYSA-N 4-[5-[[5-(3,4-dimethoxyphenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C(O1)=CC=C1C=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)C(=S)S1 PGLXDIOYDKBTCB-UHFFFAOYSA-N 0.000 claims description 2
- CMVYURLAWKBMHR-UHFFFAOYSA-N 4-[5-[[5-(3,4-dimethylphenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=C(C)C(C)=CC=C1C(O1)=CC=C1C=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)C(=S)S1 CMVYURLAWKBMHR-UHFFFAOYSA-N 0.000 claims description 2
- KAKMEYLZRRDRDL-UHFFFAOYSA-N 4-[5-[[5-(3,5-dichlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C=C(Cl)C=C(Cl)C=2)O1 KAKMEYLZRRDRDL-UHFFFAOYSA-N 0.000 claims description 2
- QVBAYPGAGQONNU-UHFFFAOYSA-N 4-[5-[[5-(3,5-difluorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C=C(F)C=C(F)C=2)O1 QVBAYPGAGQONNU-UHFFFAOYSA-N 0.000 claims description 2
- IQEMUNAZZKSNPT-UHFFFAOYSA-N 4-[5-[[5-(3,5-dimethylphenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound CC1=CC(C)=CC(C=2OC(C=C3C(N(C(=S)S3)C=3C=CC(=CC=3)C(O)=O)=O)=CC=2)=C1 IQEMUNAZZKSNPT-UHFFFAOYSA-N 0.000 claims description 2
- NWZCZFWXKMTBTR-UHFFFAOYSA-N 4-[5-[[5-(4,5-dichloro-1h-imidazol-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2NC(Cl)=C(Cl)N=2)O1 NWZCZFWXKMTBTR-UHFFFAOYSA-N 0.000 claims description 2
- ISIXSWDLOVMMKT-UHFFFAOYSA-N 4-[5-[[5-(4,6-dimethylpyridin-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound CC1=CC(C)=NC(C=2OC(C=C3C(N(C(=S)S3)C=3C=CC(=CC=3)C(O)=O)=O)=CC=2)=C1 ISIXSWDLOVMMKT-UHFFFAOYSA-N 0.000 claims description 2
- CNCBXYARQRMKFC-UHFFFAOYSA-N 4-[5-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C=CC(Cl)=CC=2)O1 CNCBXYARQRMKFC-UHFFFAOYSA-N 0.000 claims description 2
- YCPNUIIAOSZMAS-UHFFFAOYSA-N 4-[5-[[5-(4-methoxyphenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(OC)=CC=C1C(O1)=CC=C1C=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)C(=S)S1 YCPNUIIAOSZMAS-UHFFFAOYSA-N 0.000 claims description 2
- SFYSXOKPPQKQKS-UHFFFAOYSA-N 4-[5-[[5-(4-methylpyridin-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound CC1=CC=NC(C=2OC(C=C3C(N(C(=S)S3)C=3C=CC(=CC=3)C(O)=O)=O)=CC=2)=C1 SFYSXOKPPQKQKS-UHFFFAOYSA-N 0.000 claims description 2
- JTAVXQLUSKNREB-UHFFFAOYSA-N 4-[5-[[5-(5-chloro-3-methyl-1-benzothiophen-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound S1C2=CC=C(Cl)C=C2C(C)=C1C(O1)=CC=C1C=C(C1=O)SC(=S)N1C1=CC=C(C(O)=O)C=C1 JTAVXQLUSKNREB-UHFFFAOYSA-N 0.000 claims description 2
- NZGFSGUDQBJRSU-UHFFFAOYSA-N 4-[5-[[5-(5-chlorothiophen-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2SC(Cl)=CC=2)O1 NZGFSGUDQBJRSU-UHFFFAOYSA-N 0.000 claims description 2
- NEYFWZVLOCPPEC-UHFFFAOYSA-N 4-[5-[[5-(5-methylthiophen-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound S1C(C)=CC=C1C(O1)=CC=C1C=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)C(=S)S1 NEYFWZVLOCPPEC-UHFFFAOYSA-N 0.000 claims description 2
- CRQCRYCCEXEOGW-UHFFFAOYSA-N 4-[5-[[5-(6-methoxypyridazin-3-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound N1=NC(OC)=CC=C1C(O1)=CC=C1C=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)C(=S)S1 CRQCRYCCEXEOGW-UHFFFAOYSA-N 0.000 claims description 2
- RKWBABVTVZEDHS-UHFFFAOYSA-N 4-[5-[[5-(furan-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2OC=CC=2)O1 RKWBABVTVZEDHS-UHFFFAOYSA-N 0.000 claims description 2
- OVVIPVWDOLGJBB-UHFFFAOYSA-N 4-[[5-[[5-[2-chloro-5-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]methylidene]cyclohexa-1,5-diene-1-carboxylic acid Chemical compound C1=CC(C(=O)O)=CCC1=CN(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)O1 OVVIPVWDOLGJBB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- QLGNCJVXTYVXEJ-UHFFFAOYSA-N 4-[5-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C=C(Cl)C(Cl)=CC=2)O1 QLGNCJVXTYVXEJ-UHFFFAOYSA-N 0.000 claims 3
- UMJDAKOQRLTQHO-UHFFFAOYSA-N 4-[5-[[5-(5-chlorothiophen-2-yl)-1,3-thiazol-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=NC=C(C=2SC(Cl)=CC=2)S1 UMJDAKOQRLTQHO-UHFFFAOYSA-N 0.000 claims 3
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 claims 2
- NNJLZQPPMGXPAJ-UHFFFAOYSA-N 2-[4-oxo-2-sulfanylidene-5-[[5-[3-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-1,3-thiazolidin-3-yl]acetic acid Chemical compound O=C1N(CC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)O1 NNJLZQPPMGXPAJ-UHFFFAOYSA-N 0.000 claims 1
- CNYIHZMWZVWMRN-UHFFFAOYSA-N 2-[5-[[5-(3,5-dichlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid Chemical compound O=C1N(CC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=C(Cl)C=C(Cl)C=2)O1 CNYIHZMWZVWMRN-UHFFFAOYSA-N 0.000 claims 1
- VCALAHVGQVBMSG-UHFFFAOYSA-N 2-[5-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid Chemical compound O=C1N(CC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=CC(Cl)=CC=2)O1 VCALAHVGQVBMSG-UHFFFAOYSA-N 0.000 claims 1
- PETNXDAIJDCWQA-UHFFFAOYSA-N 3-[4-oxo-2-sulfanylidene-5-[(5-thiophen-2-ylfuran-2-yl)methylidene]-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2SC=CC=2)O1 PETNXDAIJDCWQA-UHFFFAOYSA-N 0.000 claims 1
- BRAWBQFKVFOXBF-UHFFFAOYSA-N 3-[5-[[5-(5-methylthiophen-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound S1C(C)=CC=C1C(O1)=CC=C1C=C1C(=O)N(CCC(O)=O)C(=S)S1 BRAWBQFKVFOXBF-UHFFFAOYSA-N 0.000 claims 1
- LFJPRHBSSZGMIS-UHFFFAOYSA-N 3-[5-[[5-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophen-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound CN1N=C(C(F)(F)F)C=C1C(S1)=CC=C1C=C1C(=O)N(C=2C=C(C=CC=2)C(O)=O)C(=S)S1 LFJPRHBSSZGMIS-UHFFFAOYSA-N 0.000 claims 1
- YIFLICAOHCMRBQ-UHFFFAOYSA-N 4-[5-[[4-(5-chlorothiophen-2-yl)-1,3-thiazol-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=NC(C=2SC(Cl)=CC=2)=CS1 YIFLICAOHCMRBQ-UHFFFAOYSA-N 0.000 claims 1
- GPDJBVYNBNWHNI-UHFFFAOYSA-N 4-[5-[[5-(2,5-dichlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C(=CC=C(Cl)C=2)Cl)O1 GPDJBVYNBNWHNI-UHFFFAOYSA-N 0.000 claims 1
- SXARUAGCZYUIQG-UHFFFAOYSA-N 4-[5-[[5-(2-nitrophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C(=CC=CC=2)[N+]([O-])=O)O1 SXARUAGCZYUIQG-UHFFFAOYSA-N 0.000 claims 1
- YUDQJZDSYCWPNI-UHFFFAOYSA-N 4-[5-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid 4-[4-oxo-5-[[5-(2-phenylethynyl)furan-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound ClC=1C=C(C=CC1Cl)C1=CC=C(O1)C=C1C(N(C(S1)=S)C1=CC=C(C(=O)O)C=C1)=O.C1(=CC=CC=C1)C#CC1=CC=C(O1)C=C1C(N(C(S1)=S)C1=CC=C(C(=O)O)C=C1)=O YUDQJZDSYCWPNI-UHFFFAOYSA-N 0.000 claims 1
- LJYMFINBBHXVLB-UHFFFAOYSA-N 4-[5-[[5-(4,5-dimethylfuran-2-yl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound O1C(C)=C(C)C=C1C(O1)=CC=C1C=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)C(=S)S1 LJYMFINBBHXVLB-UHFFFAOYSA-N 0.000 claims 1
- AUVOIFIFVVINEL-UHFFFAOYSA-N 4-[5-[[5-(4-butylphenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(CCCC)=CC=C1C(O1)=CC=C1C=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)C(=S)S1 AUVOIFIFVVINEL-UHFFFAOYSA-N 0.000 claims 1
- YQNBKPVAOYRVOQ-UHFFFAOYSA-N 4-[5-[[5-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C(=CC(=CN=2)C(F)(F)F)Cl)O1 YQNBKPVAOYRVOQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical class O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 abstract description 11
- 235000010233 benzoic acid Nutrition 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 4
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000007787 solid Substances 0.000 description 19
- 108060004795 Methyltransferase Proteins 0.000 description 17
- 238000010992 reflux Methods 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 10
- 229940093499 ethyl acetate Drugs 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 7
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 5
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 5
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical class O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 5
- WABBMXFNRFZTOX-UHFFFAOYSA-N 2-bromo-5-(dimethoxymethyl)furan Chemical compound COC(OC)C1=CC=C(Br)O1 WABBMXFNRFZTOX-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
- 208000001490 Dengue Diseases 0.000 description 3
- 206010012310 Dengue fever Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000025729 dengue disease Diseases 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GQECANUIPBFPLA-UHFFFAOYSA-N 2-(carboxymethylsulfanylcarbothioylsulfanyl)acetic acid Chemical compound OC(=O)CSC(=S)SCC(O)=O GQECANUIPBFPLA-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000531123 GB virus C Species 0.000 description 2
- 241000414862 GBV-A-like agents Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 208000004571 Pestivirus Infections Diseases 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108700017026 flavivirus NS5 Proteins 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 208000025858 pestivirus infectious disease Diseases 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 0 **N(C(*C1=*=C*)=*)C1=* Chemical compound **N(C(*C1=*=C*)=*)C1=* 0.000 description 1
- UQLANBZLKVLADA-UHFFFAOYSA-N 1-methyl-5-(trifluoromethyl)pyrazole Chemical compound CN1N=CC=C1C(F)(F)F UQLANBZLKVLADA-UHFFFAOYSA-N 0.000 description 1
- FRDVTZNXPZPLBJ-UHFFFAOYSA-N 2,3,4-tributylfuran Chemical class CCCCC1=COC(CCCC)=C1CCCC FRDVTZNXPZPLBJ-UHFFFAOYSA-N 0.000 description 1
- WAEZQBAYTOSVOE-UHFFFAOYSA-N 2-(2-chloro-5-nitrophenyl)-5-(dimethoxymethyl)thiophene Chemical compound S1C(C(OC)OC)=CC=C1C1=CC([N+]([O-])=O)=CC=C1Cl WAEZQBAYTOSVOE-UHFFFAOYSA-N 0.000 description 1
- JGRMXPSUZIYDRR-UHFFFAOYSA-N 2-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)acetic acid Chemical compound OC(=O)CN1C(=O)CSC1=S JGRMXPSUZIYDRR-UHFFFAOYSA-N 0.000 description 1
- IBPAJWXNXAWGLT-UHFFFAOYSA-N 2-[4-oxo-2-sulfanylidene-5-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methylidene]-1,3-thiazolidin-3-yl]acetic acid Chemical compound O=C1N(CC(=O)O)C(=S)SC1=CC1=CC=CC(OC=2C=C(C=CC=2)C(F)(F)F)=C1 IBPAJWXNXAWGLT-UHFFFAOYSA-N 0.000 description 1
- ZTGJLQZRBVUNPS-UHFFFAOYSA-N 2-bromo-5-(dimethoxymethyl)thiophene Chemical compound COC(OC)C1=CC=C(Br)S1 ZTGJLQZRBVUNPS-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- OFWADGOJEMSXMK-UHFFFAOYSA-N 2-sulfanylidene-5-[(5-thiophen-2-ylthiophen-2-yl)methylidene]-1,3-thiazolidin-4-one Chemical compound O=C1NC(=S)SC1=CC1=CC=C(C=2SC=CC=2)S1 OFWADGOJEMSXMK-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- QBQQLAKCTHTRAQ-UHFFFAOYSA-N 3-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC(N2C(SCC2=O)=S)=C1 QBQQLAKCTHTRAQ-UHFFFAOYSA-N 0.000 description 1
- CYMFMMWIDGLPFU-UHFFFAOYSA-N 3-[4-oxo-2-sulfanylidene-5-[[5-(1,3-thiazol-2-yl)furan-2-yl]methylidene]-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2SC=CN=2)O1 CYMFMMWIDGLPFU-UHFFFAOYSA-N 0.000 description 1
- OYZDZSRXJNSBFW-UHFFFAOYSA-N 3-[4-oxo-5-[[5-(5-propylthiophen-2-yl)furan-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound S1C(CCC)=CC=C1C(O1)=CC=C1C=C1C(=O)N(CCC(O)=O)C(=S)S1 OYZDZSRXJNSBFW-UHFFFAOYSA-N 0.000 description 1
- YGZJYOBCYLYGGB-UHFFFAOYSA-N 3-[5-[[5-(3,5-dichlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid Chemical compound O=C1N(CCC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=C(Cl)C=C(Cl)C=2)O1 YGZJYOBCYLYGGB-UHFFFAOYSA-N 0.000 description 1
- GYORTKHHBDTZHY-UHFFFAOYSA-N 4-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1C(=S)SCC1=O GYORTKHHBDTZHY-UHFFFAOYSA-N 0.000 description 1
- XOKTXQZCVARUHE-UHFFFAOYSA-N 4-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=S)SCC1=O XOKTXQZCVARUHE-UHFFFAOYSA-N 0.000 description 1
- XVPRGFCQVYJWBS-UHFFFAOYSA-N 4-[4-oxo-2-sulfanylidene-5-[[5-[3-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)O1 XVPRGFCQVYJWBS-UHFFFAOYSA-N 0.000 description 1
- UYLSQBCBBYDVAE-UHFFFAOYSA-N 4-[4-oxo-2-sulfanylidene-5-[[5-[5-(trifluoromethyl)pyridin-2-yl]furan-2-yl]methylidene]-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2N=CC(=CC=2)C(F)(F)F)O1 UYLSQBCBBYDVAE-UHFFFAOYSA-N 0.000 description 1
- FOTJAQBLBDLXRE-UHFFFAOYSA-N 4-[4-oxo-5-[[5-(2-phenylethynyl)furan-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C#CC=2C=CC=CC=2)O1 FOTJAQBLBDLXRE-UHFFFAOYSA-N 0.000 description 1
- GBZWJTSHYITMOY-UHFFFAOYSA-N 4-[5-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoic acid Chemical compound O=C1N(CCCC(=O)O)C(=S)SC1=CC1=CC=C(C=2C=C(Cl)C(Cl)=CC=2)O1 GBZWJTSHYITMOY-UHFFFAOYSA-N 0.000 description 1
- TVYNYVIHSVCARI-UHFFFAOYSA-N 4-[5-[[5-(4-bromophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C=CC(Br)=CC=2)O1 TVYNYVIHSVCARI-UHFFFAOYSA-N 0.000 description 1
- SEILVEGRXAQDNW-UHFFFAOYSA-N 4-[[5-[[5-[2-chloro-5-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN(C(=S)S1)C(=O)C1=CC1=CC=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)O1 SEILVEGRXAQDNW-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- ONQOZTFAOFZDFK-UHFFFAOYSA-N 5-(2-chlorophenyl)furan-2-carbaldehyde Chemical compound ClC1=CC=CC=C1C1=CC=C(C=O)O1 ONQOZTFAOFZDFK-UHFFFAOYSA-N 0.000 description 1
- PSQLTDROSWBPGT-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)furan-2-carbaldehyde Chemical compound C1=C(Cl)C(Cl)=CC=C1C1=CC=C(C=O)O1 PSQLTDROSWBPGT-UHFFFAOYSA-N 0.000 description 1
- BDUFOVWZBTVLPY-UHFFFAOYSA-N 5-[2-chloro-5-(trifluoromethyl)phenyl]furan-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(Cl)C(C=2OC(C=O)=CC=2)=C1 BDUFOVWZBTVLPY-UHFFFAOYSA-N 0.000 description 1
- SZISGRQTIWEEDU-UHFFFAOYSA-N 5-[[5-(2-chloro-5-nitrophenyl)thiophen-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound [O-][N+](=O)C1=CC=C(Cl)C(C=2SC(C=C3C(NC(=S)S3)=O)=CC=2)=C1 SZISGRQTIWEEDU-UHFFFAOYSA-N 0.000 description 1
- SYSPQVSFYJERIH-UHFFFAOYSA-N 5-[[5-(3,4-dichlorophenyl)thiophen-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C(S1)=CC=C1C=C1C(=O)NC(=S)S1 SYSPQVSFYJERIH-UHFFFAOYSA-N 0.000 description 1
- XPLGVNDNCGJEJP-UHFFFAOYSA-N 5-[[5-(4-methylphenyl)thiophen-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(C)=CC=C1C(S1)=CC=C1C=C1C(=O)NC(=S)S1 XPLGVNDNCGJEJP-UHFFFAOYSA-N 0.000 description 1
- KJTRHFHKEAZWME-UHFFFAOYSA-N 5-[[5-(4-propylphenyl)thiophen-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(CCC)=CC=C1C(S1)=CC=C1C=C1C(=O)NC(=S)S1 KJTRHFHKEAZWME-UHFFFAOYSA-N 0.000 description 1
- BPRSBRLAEGVZLR-UHFFFAOYSA-N 5-[[5-[2-chloro-5-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound FC(F)(F)C1=CC=C(Cl)C(C=2OC(C=C3C(NC(=S)S3)=O)=CC=2)=C1 BPRSBRLAEGVZLR-UHFFFAOYSA-N 0.000 description 1
- WJTFHWXMITZNHS-UHFFFAOYSA-N 5-bromofuran-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)O1 WJTFHWXMITZNHS-UHFFFAOYSA-N 0.000 description 1
- GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 1
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001118702 Border disease virus Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010054261 Flavivirus infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710843 Japanese encephalitis virus group Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000004768 bromobenzenes Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Substances ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000017580 chronic wasting disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ASKSDLRLUXEOOR-SUFRFZPQSA-N gbv-c Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC(C)C)=CNC2=C1 ASKSDLRLUXEOOR-SUFRFZPQSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical class CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N phenyl bromide Natural products BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 241001147422 tick-borne encephalitis virus group Species 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- HIZCIEIDIFGZSS-UHFFFAOYSA-L trithiocarbonate Chemical compound [S-]C([S-])=S HIZCIEIDIFGZSS-UHFFFAOYSA-L 0.000 description 1
- 239000012989 trithiocarbonate Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to novel rhodanine derivatives and analogs, as well as compositions containing the same and to the use thereof for treating or preventing viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by viruses within the Flaviviridae family.
- the Flaviviridae family consists of three genera and several viruses that are currently unassigned to specific genera.
- the hepacivirus genus includes the hepatitis C viruses (HCV).
- HCV hepatitis C viruses
- Viruses such as GB virus-A and GB virus- A-like agents, GB virus-B and GBV-C or hepatitis G virus, while at present not formally classified within the hepacivirus genus, are closely related to HCV and represent unassigned members of the Flaviviridae family.
- the pestivirus genus which includes bovine viral diarrhea viruses (BVDV), border disease viruses and classical swine fever virus, and the flavivirus genus, with viruses such as dengue, yellow fever, Japanese encephalitis and tick-borne encephalitis viruses.
- BVDV bovine viral diarrhea viruses
- border disease viruses border disease viruses
- classical swine fever virus the flavivirus genus, with viruses such as dengue, yellow fever, Japanese encephalitis and tick-borne encephalitis viruses.
- HCV hepatitis .
- the World Health Organization estimates that 170 million people worldwide are presently infected with the virus. Most infections become persistent and about 60% of cases develop chronic liver disease. Chronic HCV infection can lead to development of cirrhosis, hepatocellular carcinoma and liver failure.
- Interferon and interferon in combination with ribavirin are used in the U.S. for hepatitis due to HCV. These treatments are associated with improved serum enzyme response in some patients. The remainder are non-responsive to treatment. For responders, a sustained clinical improvement is seen in only a small percentage of patients; the majority of patients relapse upon cessation of treatment. Thus, the effectiveness of therapy for chronic hepatitis C is variable and its cure rate remains low. Moreover, therapy is often associated with considerable side effects.
- Pestivirus infections of domesticated livestock cause significant economic losses worldwide. Pestiviruses cause a range of clinical manifestations including abortion, teratogenesis, respiratory problems, chronic wasting disease, immune system dysfunction and predisposition to secondary viral and bacterial infections.
- BVDV strains cause an acute fatal disease.
- BVDV can also establish persistent infections in fetuses. When born, these persistently infected (PI) animals remain viremic throughout life and serve as continuous virus reservoirs. PI animals often succumb to fatal mucosal disease.
- Flaviviruses are important pathogens of man and are also prevalent throughout the world. There are at least 38 flaviviruses associated with human disease, including the dengue fever viruses, yellow fever virus and Japanese encephalititis virus. Flaviviruses cause a range of acute febrile illnesses and encephalitic and hemorrhagic diseases. Currently, there are no antiviral pharmaceuticals to prevent or treat pestivirus or flavivirus infections.
- virus-specific functions that may be exploited in such approaches.
- enzymatic activities of virus-encoded polypeptides are quite useful.
- These virus-specified components are often essential for virus replication and may be suitable targets for antiviral drug discovery strategies.
- One such target that plays a central role in the life cycle of many RNA viruses is the virus-encoded RNA-dependent RNA polymerase (RdRp) protein.
- this protein is termed NS5B in the case of the hepaciviruses and pestiviruses, and NS5 in the case of the flaviviruses (collectively referred to as NS5).
- RdRp proteins are a key component of the virus replicase complex, enabling the virus to replicate its RNA genome and produce progeny viruses.
- the RdRp of RNA viruses is an attractive target for antiviral drug development.
- a method of treating or preventing infection caused by at least one virus of the Flaviviridae and disease associated with such infection in a living host having or susceptible to such infection comprises administering to the infected or susceptible host a therapeutically or prophylactically effective amount of a compound, or precursor of said compound, having the formula:
- R represents hydrogen or alkyl; and m is an integer from 0-4;
- R represents hydrogen or a radical selected from those consisting of an -R 3 COOH radical, wherein R 3 is an unsubstituted or substituted, branched or straight chain, saturated or unsaturated hydrocarbon moiety of 1-10 carbon atoms, an unsubstituted or substituted phenyl (C 6 H 5 ) radical or an unsubstituted or substituted phenylalkyl radical, the R 3 substituents being at least one selected from those consisting of a branched or straight chain, saturated or unsaturated aliphatic group having 1 -6 carbon atoms, an unsubstituted or substituted heterocyclic radical or an unsubstituted or substituted phenyl (C 6 H 5 ) radical, said heterocyclic radical being selected from those consisting of furan, thiophene, oxazole, oxadiazole, pyridine, pyrimidine, pyrazole
- X represents a moiety selected from the group consisting of -S-, -O- or - N(R-)-, R- being hydrogen or alkyl of 1-5 carbon atoms;
- R 2 represents a radical selected from those consisting of an unsubstituted or substituted phenylalkyl radical, an unsubstituted or substituted phenylalkenyl radical, an unsubstituted or substituted phenylalkynyl radical, an unsubstituted or substituted biphenylalkyl radical, an unsubstituted or substituted polycyclic radical, an unsubstituted or substituted alicyclic radical having 5-8 carbon atoms or a radical of the formula (R 2a -) n (L-) p R b - > wherein R 2a and R 2b may be the same or different and represent an unsubstituted or substituted heterocyclic radical or an unsubstituted or substituted phenyl radical
- Y represents O or S
- Z represents O, S or N(R b ), R b being hydrogen or alkyl; or R, and R b may be joined to form an imidazole or a benzimidazole moiety; and the isomers and pharmaceutically acceptable salts of the compound.
- Infections caused by Flaviviridae viruses and associated diseases may be effectively treated or prevented by administering a compound of the formula:
- R represents hydrogen or a radical selected from those consisting of -R 3 COOH, wherein R 3 is a branched or straight chain aliphatic moiety of 1-10 carbon atoms, or an unsubstituted, or substituted phenyl (C 6 H 5 ) group;
- X represents a moiety selected from the group consisting of -S-, -O- or -
- R_ being hydrogen or alkyl of 1-5 carbon atoms
- Y represents O or S
- Z represents O, S or N(R,,), R b being hydrogen or alkyl of 1-5 carbon atoms; or R, and R b may be joined to form a benzimidazole moiety; and the isomers and pharmaceutically acceptable salts of the compound.
- compositions for treating or preventing viral infections comprise an anti-viral agent in an amount effective to attenuate viral infectivity, and a pharmaceutically acceptable carrier medium.
- the composition of the invention comprises a compound of the formula:
- R represents hydrogen or alkyl
- m is an integer from 0-4;
- R 3 represents an unsubstituted or substituted, branched or straight chain, saturated or unsaturated hydrocarbon moiety having 1-10 carbon atoms in the main chain, the hydrocarbon moiety substituents being at least one selected from those consisting of a branched or straight chain, saturated or unsaturated aliphatic group, having 1 -6 carbon atoms, an unsubstituted or substituted heterocyclic radical or an unsubstituted or substituted phenyl (C 6 H 5 ) radical, the heterocyclic radical being selected from those consisting of furan, thiophene, oxazole, oxadiazole, pyridine, pyrimidine, pyrazole, triazole, pyridazine, 1,3-oxathiolane, thiazole, thiadiazole, imidazole, tetrazole, pyrrole and triazine; and R 2 , X, Y, Z and the substituents of the heterocyclic radicals
- R 3 represents an unsubstituted or substituted, branched or straight chain, saturated or unsaturated aliphatic moiety having 1-10 carbon atoms in the main chain, the aliphatic moiety substituents being selected from those consisting of at least one branched or straight chain, saturated or unsaturated aliphatic group, having 1 -6 carbon atoms, unsubstituted or substituted mono-heterocyclic group or unsubstituted or substituted phenyl (C 6 H 5 ) group, the heterocyclic group being selected from those consisting of furan, thiophene, oxazole, oxadiazole, pyridine, pyrimidine, pyrazole, triazole, pyridazine, 1,3-oxathiolane, thiazole, thiadiazole, imidazole, tetrazole, pyrrole and triazine.
- X represents a moiety selected from the group consisting of -S-
- R_ being hydrogen or alkyl
- composition of the invention comprises a compound of the formula:
- R represents hydrogen or alkyl
- m is an integer from
- R represents hydrogen or a substituent selected from the group consisting of -OH, -COOR 4 , -CONRsRe, -SO 2 NR 7 R 8 , R 4 , R 5 , R «, R 7 and R 8 being independently selected from the group of hydrogen or alkyl, or R, represents a mono-heterocylic radical selected from the group of furan, thiophene, pyridine, pyrimidine, pyridazine, 1,3-oxathiolane, tetrazole, oxadiazole, oxazole, triazole, imidazoline, imidazole, thiazole, thiadiazole, pyrrole, piperidine, morpholine, triazine and pyrazole;
- W and W may be the same or different and represent hydrogen or a substituent selected from the group consisting of a straight or branched chain, saturated or unsaturated aliphatic group having 1 -6 carbon atoms, hal
- R represents hydrogen or a substituent selected from the group consisting of -OH, -COOR 3 , -CONR 4 R 5 , -SO.NR ⁇ , R 3 , R,, R 5 , R « and R 7 being independently selected from the group of hydrogen, alkyl, or R, represents a heterocylic ring selected from the group of tetrazole, oxadiazole, oxazole, triazole, imidazoline, imidazole, thiazole, thiadiazole, pyrrole, piperidine, morpholine and pyrazole;
- W and W may be the same or different and represent hydrogen or a substituent selected from the group consisting of a straight or branched chain, saturated or unsaturated aliphatic group having 1-6 carbon atoms, halogen, nitro, hydroxy, perfluoroalkyl, difluoromethyl, alkoxy, phenoxy, acyloxy, cyano, carbalkoxy, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylamino, dialkylamino, sulfonamide, carboxamide and alkanoylamino.
- t is an integer from 0 to 8;
- X represents a moiety selected from the group consisting of -S-, -O- or - N(RJ-, R a being hydrogen or alkyl;
- Y represents O or S
- Z represents O, S or N(R b ), R b being hydrogen or alkyl; or R, and R b may be joined to form an imidazole or benzimidazole moiety; and the isomers and pharmaceutically acceptable salts of the compound.
- R 2 radical in formulas II and III, above is of the formula (R 2a -)n (L-)pR. 2b -, p is 0; and m is 0.
- R 3 represents an unsubstituted or substituted, branched or straight chain, saturated or unsaturated hydrocarbon moiety having 1-10 carbon atoms in the main chain, the hydrocarbon moiety substituents being at least one selected from those consisting of a branched or straight chain, saturated or unsaturated aliphatic group, having 1-6 carbon atoms, unsubstituted or substituted mono- heterocyclic group or unsubstituted or substituted phenyl (C 6 H 5 ) group, the mono-heterocyclic group being selected from those consisting of furan, thiophene, oxazole, oxadiazole, pyridine, pyrimidine, pyrazole, triazole, pyridazine, 1,3-oxathiolane, thiazole, thiadiazole, imidazole, tetrazole, pyrrole and triazine;
- X represents a moiety selected from the group consisting of -S-, -O- or - N(R a )-, R a being hydrogen or alkyl;
- R 2 represents a radical selected from those consisting of an unsubstituted or substituted mono- or bi-heterocyclic radical, an unsubstituted or substituted polycyclic radical, an unsubstituted or substituted polycyclic-heterocyclic radical, an unsubstituted or substituted alicyclic radical having 5-8 carbon atoms, an unsubstituted or substituted phenyl radical, an unsubstituted or substituted biphenyl (C 6 H 5 -C 6 H 4 -) radical, an unsubstituted or substituted phenyl ether
- (C 6 H 5 -O-C 6 H 4 -) radical or an unsubstituted or substituted 2-phenylethenyl (C 6 H 5 CH CH-) radical
- said mono-heterocyclic group being selected from those consisting of furan, thiophene, oxazole, oxadiazole, pyridine, pyrimidine, pyrazole, triazole, pyridazine, 1,3-oxathiolane, thiazole, thiadiazole, imidazole, tetrazole, pyrrole and triazine
- said bi-heterocyclic group comprising two heterocyclic moieties which are selected from the mono-heterocyclic radical group members, and which may be the same or different
- said polycyclic ring moiety being selected from those consisting of benzofuran, isobenzo furan, benzothiophene, isobenzothiophene, benzoxazole, indole, 2-
- 1,2,3-benzotriazole benzothiazole, benzimidazole, 1,2,3-benzotriazine and 1,2,4- benzotriazine, naphthalene, anthracene and fluorene and said polycyclic- heterocyclic radical comprising a polycyclic moiety selected from said polycyclic radical group members and a heterocyclic moiety which is selected from the mono-heterocyclic radical group members; the mono-heterocyclic radical substituents, the bi-heterocyclic radical substituents, the alicyclic radical substituents, the polycyclic radical substituents and the polycyclic-heterocyclic radical substituents being at least one selected from those consisting of a straight or branched chain, saturated or unsaturated aliphatic group having 1-6 carbon atoms, halogen, trifluoromethyl, alkoxy, hydroxy, thio, nitro, carbalkoxy, an unsubstituted or substituted phenyl radical,
- Y represents O or S
- Z represents O, S or N(R b ), R,, being hydrogen or alkyl; or R, and R b may be joined to form an imidazole or benzimidazole moiety; and the isomers and pharmaceutically acceptable salts of the compound.
- R represents hydrogen or a substituent selected from the group consisting of -OH, -COOH, R,, R 5 , Re and R 7 being independently selected from the group of hydrogen, alkyl, or R, represents a heterocylic ring selected from the group of furan, thiophene, pyridine, pyrimidine, pyridazine, 1,3-oxathiolane, tetrazole, oxadiazole, oxazole, triazole, imidazoline, imidazole, thiazole, thiadiazole, pyrrole, piperidine, morpholine, triazine and pyrazole;
- W may be the same or different and represent hydrogen or a substituent selected from the group consisting of a straight or branched chain, saturated or unsaturated aliphatic group having 1 -6 carbon atoms, halogen, nitro, hydroxy, perfluoroalkyl, difluoromethyl, alkoxy, phenoxy, acyloxy, cyano, carbalkoxy, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylamino, dialkylamino, sulfonamido, carboxamido and alkanoylamino.
- t is an integer from 0 to 8;
- X represents a moiety selected from the group consisting of -S-, -O- or - N(R_)-, R a being hydrogen or alkyl;
- R 2 represents a radical selected from those consisting of an unsubstituted or substituted mono- or bi-heterocyclic radical, an unsubstituted or substituted polycyclic radical, an unsubstituted or substititued polycyclic-heterocyclic radical, an unsubstituted or substituted alicyclic radical having 5-8 carbon atoms, an unsubstituted or substituted phenyl radical, an unsubstituted or substituted biphenyl ( H 5 -C 6 H 4 -) radical, an unsubstituted or substituted phenyl ether
- the mono-heterocyclic radical being selected from those consisting of furan, thiophene, oxazole, oxadiazole, pyridine, pyrimidine, pyrazole, triazole, pyridazine, 1,3-oxathiolane, thiazole, thiadiazole, imidazole, tetrazole, pyrrole and triazine;
- the bi-heterocyclic group comprising two heterocyclic groups, the two heterocyclic groups being selected from said mono- heterocyclic radical group members and being the same or different, the polycyclic radical being selected from the group consisting of benzofuran, iso
- Rhodanine derivatives or analogs according to the present invention can be conveniently prepared from known starting materials by following the general synthetic scheme shown below.
- R, R,, R 2 , X, Y, Z and m are as previously defined.
- a reaction mixture which comprises the appropriate aldehyde and the appropriate rhodanine derivative or analog in ethanol, and the reaction mixture is heated to reflux in the presence of a catalytic amount of piperidine.
- the appropriate aldehyde starting materials or precursors thereof are available from commercial sources.
- various 5-substituted furaldehydes can be prepared by treating the corresponding dimethylacetal as shown below.
- 5-bromofuran-2-carboxaldehyde dimethylacetal is treated with n- butyl lithium and n-tributyltin chloride in tetrahydrofuran at -78°C to produce the tri-n-butylfuran analog which, on treatment with the appropriate substituted bromobenzene, yields the 5-substituted furan intermediate.
- Conversion of the resulting intermediate with pyridine, using a catalytic amount of pyridinium p- toluene sulfonate (PPTS), provides a 5 -(substituted phenyl) furan-2- carboxaldehyde.
- PPTS pyridinium p- toluene sulfonate
- the aldehydes may also be prepared by the method described by Pong et al.,
- Antiviral activity was measured by the inhibitory activity of the compounds against the viral RdRp in an enzymological assay for RNA synthesis.
- R 3 is a straight chain alkylene of 1-5 carbon atoms
- Y is oxygen
- X and Z are sulfur
- R 2 is an unsubstituted or substituted mono-heterocyclic radical selected from those consisting of furan, thiophene and oxazole, or an unsubstituted or substituted bi-heterocyclic radical selected from those consisting of bi-thienyl and lH-pyrazolylthienyl
- the heterocyclic radical substituents being at least one selected from those consisting of halogen, trifluoromethyl or an unsubstituted or substituted phenyl radical
- said phenyl radical substituents being at least one selected from those consisting of halogen, nitro, carboxy, hydroxy, methyl, ethyl, trifluoromethyl, difluoromethyl, alkoxy, phenoxy, acyloxy, cyano, carbalkoxy
- R 3 is a straight chain alkylene of 1 -5 carbon atoms
- Y is oxygen
- X and Z are sulfur
- R 2 is an unsubstituted or substituted phenyl radical
- the phenyl radical substituents being at least one selected from those consisting of halogen, nitro, carboxy, hydroxy,methyl, ethyl, trifluoromethyl, difluoromethyl, alkoxy, phenoxy, acyloxy, cyano, carbalkoxy, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylamino, dialkylamino, sulfonamido, carboxamido, alkanoylamino, 1- pyrrolidinyl, 1 -piperidinyl or 4-morpholinyl.
- R 3 is a straight chain alkylene of 1 -5 carbon atoms
- Y is oxygen
- X and Z are sulfur and
- R 2 is an unsubstituted or substituted polycyclic radical selected from those consisting of 9-phenanthryl and 2-fluorenyl, said polycyclic radical substituents being at least one selected from those consisting of methyl, ethyl, halogen, alkoxy, hydroxy, thio, nitro or an unsubstituted or substituted phenyl radical, the phenyl radical substituents being at least one selected from those consisting of halogen, nitro, carboxy, hydroxy,methyl, ethyl, trifluoromethyl, difluoromethyl, alkoxy, phenoxy, acyloxy, cyano, carbalkoxy, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylamino, dialkylamino, sulfonamido, carboxamido, alkanoylamino, 1-pyrolidyl, 1 -piperidinyl
- R is a carboxyl group
- W and W represent hydrogen, halogen, hydroxy, alkyl or trifluoromethyl substituents
- Y is oxygen
- X and Z are sulfur
- R 2 in the compounds of formulas II and III, above, is also preferably an unsubstituted or substituted thiazole, the thiazole substituents being the same as the furan and thiophene substituents in the next preceding paragraph.
- R is a carboxyl group
- W and W represent hydrogen, halogen, hydroxy or trifluoromethyl substituents
- Y is oxygen
- X and Z are sulfur
- R 2 represents an unsubstituted or substituted phenyl group, the phenyl substituent(s) being at least one selected from those consisting of halogen, alkoxy, carboxy, an unsubstituted or substituted 2-phenylethenyl group, an unsubstituted or substituted furan group, or an unsubstituted or substituted thiophene group, the 2-phenylethenyl substituent(s), the furan substituent(s) and the thiophene substituent(s) being at least one selected from those consisting of a straight or branched chain, saturated or unsaturated aliphatic group having 1-6 carbon atoms, halogen, nitro, carboxy, hydroxy, trifluoromethyl, difluoro
- W and W' also preferably represent methyl (CH 3 ) groups.
- alkyl refers to aliphatic hydrocarbon radicals of one to six carbon atoms in length.
- alkyl or any variation thereof, used in combination form to name substituents, such as alkoxy, alkylthio, alkylamino, alkylsulfinyl or alkylsulfonyl also refers to aliphatic hydrocarbon radicals of one to six carbon atoms in length.
- acyl is used herein in accordance with its ordinary meaning to refer to an organic radical derived from a carboxy lie acid by the removal of the hydroxyl group, such as acetyl, benzoyl or the like.
- sulfonamido refers to a radical or substituent of the formula -SO 2 -NR"R'" or -NR"-SO 2 R'", wherein R" and R'" are as previously defined.
- carbbalkoxy refers to a radical or substituent
- bi-heterocyclic group is used herein to describe a radical comprising two heterocyclic moieties, which may be the same or different, that are chemically linked to one another by a valence bond or a divalent linking moiety such as oxygen or sulfur. See, for instance, entries V9 and V33 in Table
- the above-described class of rhodanine derivatives and analogs thereof, as well as their isomers and pharmaceutically acceptable salts exhibit antiviral activity.
- the compounds of the invention are particularly effective against viruses of the Flaviviridae family and are useful in treating and/or preventing infections and diseases associated with these viruses in living hosts.
- the compounds of the invention or precursors thereof and their isomers and pharmaceutically acceptable salts are also useful in treating and preventing viral infections and diseases in living hosts when used in combination with other active agents, including but not limited to interferons, ribavirin, protease inhibitors, immunoglobulins, immunomodulators, hepatoprotectants, anti- inflammatory agents, antibiotics, antivirals, anti-infectious agents, and the like.
- Compounds described herein are also useful in preventing or resolving viral infections in cell, tissue or organ cultures and other in vitro applications. For example, inclusion of compounds of the invention as a supplement in cell or tissue culture growth media and cell or tissue culture components will prevent viral infections or contaminations of cultures not previously infected with viruses. Compounds described above may also be used to eliminate viruses from cultures or other biological materials infected or contaminated with viruses (e.g., blood), after a suitable treatment period, under any number of treatment conditions as determined by the skilled artisan.
- the compounds of the invention can form useful salts with inorganic and organic acids such as hydrochloric, sulfuric, acetic, lactic, or the like, and with inorganic or organic bases such as sodium or potassium hydroxide, piperidine, mo ⁇ holine, ammonium hydroxide, or the like.
- inorganic or organic bases such as sodium or potassium hydroxide, piperidine, mo ⁇ holine, ammonium hydroxide, or the like.
- the pharmaceutically acceptable salts of the compounds of formula I are prepared following procedures that are familiar to those skilled in the art.
- compositions of the present invention comprise one or more of the compounds of the above-described formulas, as the active ingredient in combination with a pharmaceutically acceptable carrier medium or auxiliary agent and, optionally, one or more supplement active agents, as mentioned above..
- compositions may be prepared in various forms for administration, including tablets, caplets, pills or dragees, or can be filled in suitable containers, such as capsules, or, in the case of suspensions, filled into bottles.
- pharmaceutically acceptable carrier medium includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- Remington's Pharmaceutical Sciences, Fifteenth Edition, E.W. Martin (Mack Publishing Co., Easton, PA, 1975) discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof.
- any conventional carrier medium is incompatible with the antiviral compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention.
- the active agent may be present in an amount of at least 0.5% and generally not more than 90% by weight, based on the total weight of the composition, including carrier medium and/or auxiliary agent(s), if any.
- the proportion of active agent varies between 5-50% by weight of the composition.
- compositions suitable for enteral or parenteral administration can be used to make up the composition.
- Gelatin, lactose, starch, magnesium stearate, talc, vegetable and animal fats and oils, gum, polyalkylene glycol, or other known medicament components may all be suitable as carrier media or excipients.
- the compounds of the invention may be administered using any amount and any route of administration effective for attenuating infectivity of the virus.
- amount effective to attenuate infectivity of virus refers to a nontoxic but sufficient amount of the antiviral agent to provide the desired treatment of viral infection. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular antiviral agent and its mode of administration, and the like.
- the antiviral compounds are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
- dosage unit form refers to a physically discrete unit of antiviral agent appropriate for the patient to be treated.
- Each dosage should contain the quantity of active material calculated to produce the desired therapeutic effect either as such, or in association with the selected pharmaceutical carrier medium and/or the supplemental active agent(s), if any.
- the antiviral compounds of the invention will be administered in dosage units containing from about 0.1 mg to about 500 mg of the antiviral agent, with a range of about 1 mg to about 100 mg being preferred.
- the compounds of the invention may be administered as such, or in the form of a precursor from which the active agent can be derived, such as a prodrug.
- a prodrug is a derivative of a compound described herein, the pharmacologic action of which results from the conversion by chemical or metabolic processes in vivo to the active compound.
- Prodrugs include, without limitation, esters of the compounds described above, having carboxyl or hydroxy 1 functionalities. Pivaloyloxymethyl esters may be useful for this pu ⁇ ose, as well as esters prepared from simple or functionalized C,-C 6 alcohols, or from carboxylic acids.
- Such prodrugs may be prepared according to procedures well known in the field of medicinal chemistry and pharmaceutical formulation science.
- the compounds of the invention may be administered orally, rectally, parenterally, such as by intramuscular injection, subcutaneous injection, intravenous infusion or the like, intracisternally, intravaginally, intraperitoneally, locally, such as by powders, ointments, drops or the like, or by inhalation, such as by aerosol or the like, depending on the nature and severity of the infection being treated.
- the compounds of the invention may be administered at dosage levels of about 10 "3 to about 120 mg/kg of subject body weight per day and preferably from about 10 '2 to about 30 mg/kg of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
- a suitable dose for oral administration would be on the order of 30 mg/kg of body weight per day, whereas a typical intravenous dose would be on the order of 10 mg/kg of body weight per day.
- the compounds of the invention will typically be administered from 1 to 4 times a day so as to deliver the above-mentioned daily dosage.
- the exact regimen for administration of the compounds and compositions described herein will necessarily be dependent on the needs of the individual host or patient being treated, the type of treatment administered and the judgment of the attending medical specialist.
- these compounds will be useful not only for therapeutic treatment of virus infection, but for virus infection prophylaxis, as well.
- the dosages may be essentially the same, whether for treatment or prophylaxis of virus infection.
- Examples 1-8 illustrate suitable methods of synthesis of representative compounds of this invention. However, the methods of synthesis are not limited to those exemplified below.
- the reaction mixture was diluted with 100 ml of water and extracted with two portions of ethyl acetate.
- the organic layer was washed with two portions of water and followed by one portion of saturated sodium chloride and then dried over magnesium sulfate. After filtration, the solution was concentrated and then passed through a silica column and eluted with 9: 1 hexane/ethyl acetate to provide 760 mg of 5-(3,4-dichlorophenyl)-2-furaldehyde.
- Example 8 describes an alternative synthesis for preparing compounds of the present invention.
- EXAMPLE 8 4-(5-PhenyImethyIene-4-oxo-2-thionothiazoIidin-3-yI)benzoic acid a.) 4-(4-Oxo-2-thionothiazoIidin-3-yl)benzoic acid- A mixture of 6.86 g (0.05 moles) of 4-aminobenzoic acid, 11.31 g (0.025 moles) of bis(carboxymethyl)trithiocarbonate and 2.65 g (0.025 moles) of anhydrous sodium carbonate in 50 ml of water was heated to reflux for 12 hours. After cooling to room temperature, the solid which separated was collected and washed with water. After recrystallization, 7.028 g of product was obtained.
- IV-3 (5-[(5- ⁇ 3,4-dichlorophenyl ⁇ furan-2-yl)methylene]-4-oxo-2- thionothiazolidin-3-yl)acetic acid
- IV-4 4-(5-[(5- ⁇ 3,4-dichlorophenyl ⁇ furan-2-yl)methylene]-4-oxo-2- thionothiazolidin-3-yl)butyric acid
- IV-5 3-([5-(4-diethylaminophenyl)methylene]-4-oxo-2-thiono thiazolidin-3-yl)propionic acid
- IV-6 3-([5-(3-phenoxy-4-methoxyphenyl)methylene]-4-oxo-2- thionothiazolidin-3-yl)propionic acid
- IV-7 3-([5-(3,4-dichlorophenyl)methylene]-4-oxo-2- thionothiazolidin-3-yl)
- IV-8 3-([5-(9-phenanthryl)methylene]-4-oxo-2- thionothiazolidin-3-yl)propionic acid
- IV-9 3-([5-(2-fluorenyl)methylene]-4-oxo-2- thionothiazolidin-3 -yl)propionic acid
- IV-10 (5-[(5- ⁇ phenyl ⁇ furan-2-yl)methylene]-4-oxo-
- IV- 13 3-(5-[(5- ⁇ phenylethynyl ⁇ thien-2-yl)methylene]-4-oxo-2- thionothiazolidin-3 -y l)propionic acid
- IV-14 3-(5-[(5- ⁇ thien-2-yl ⁇ thien-2-yl)methylene]-4-oxo-2- thionothiazolidin-3 -yl)propionic acid
- VII- 1 3-[5-(3-phenylpropenylidenyl)-4-oxo-2- thionothiazolidin-3 -yl]benzoic acid
- VII-2 3-[5-(5- ⁇ l-methyl-5-trifluoromethyl-lH-pyrazol-3- yl ⁇ thien-2-yl)methylene-4-oxo-2-thionothiazolidin-3 - yl]benzoic acid
- VII-3 3-[5-(5- ⁇ l-methyl-3-trifluoromethyl-lH-pyrazol-5- yl ⁇ thien-2-ylmethylene)-4-oxo-2-thionothiazolidin-3 - yl]benzoic acid
- VII-4 5-(4-chlorophenyl)-2-(3 -(4-carboxypheny l)-4-oxo-2- thionothiazolidin-5-yl)idenfuran-3-yl carboxylic acid ethyl ester
- EXAMPLE 9 Inhibition of Viral RNA Replication
- an assay for the polymerase activity that is capable of high volume screening, in other words, a high-throughput assay.
- assay methodologies well known to the trained artisan that allow the efficient screening of large numbers of samples. See, for example, Cole, JL, Meth Enzymologv. 275: 310-328 (1996). Any one of these assays may be suitable in the case of a viral RdRp activity.
- Collett PCT/US99/07404, which is commonly owned with the present application, discloses compositions compirsing functional HCV NS5B sequences and their use in indentifying compounds useful in the treatment of hepacivirus infections.
- bacterially- expressed dengue flavivirus NS5 protein has been purified and shown to exhibit RdRp activity [Tan et al., Virology, 216: 317-325 (1996)], as has the NS5B protein of the pestivirus BVDV purified from recombinant baculovirus-infected cells [Zhong et al., J. Virol., 72: 9365-9369 (1998)].
- NS5 proteins prepared essentially according to Collett, PCT/US99/07404, in in vitro RdRp assays.
- Purified NS5 proteins were incubated in standard RdRp reaction mixtures.
- Such reaction mixtures generally consist of buffers, salts, cations, reducing agents and the like, as well as nucleoside triphosphates and an RNA template-primer. Variations in the individual components of such reaction mixtures may be required to accommodate the particular reaction preferences of individual NS5 proteins. Such variations are well known to the trained artisan.
- IC 50 values represent the concentration of the compound at which 50% of the RdRp activity is inhibited.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200100227A EA200100227A1 (en) | 1998-08-21 | 1999-08-19 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF VIRAL INFECTIONS AND ASSOCIATED DISEASES |
AU55702/99A AU743411B2 (en) | 1998-08-21 | 1999-08-19 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
CA002341970A CA2341970A1 (en) | 1998-08-21 | 1999-08-19 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
KR1020017002117A KR20010099623A (en) | 1998-08-21 | 1999-08-19 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
EP99942288A EP1128832A4 (en) | 1998-08-21 | 1999-08-19 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
BR9913157-9A BR9913157A (en) | 1998-08-21 | 1999-08-19 | Processes for treating or preventing infection caused by at least one virus of the flaviviridae and diseases associated with said infection and infection caused by at least one virus of the genus hepacivirus of flavivirity and diseases associated with said infection, pharmaceutical composition to treat or prevent viral infections , it's composed |
IL14145699A IL141456A0 (en) | 1998-08-21 | 1999-08-19 | Rhodanine derivatives and pharmaceutical compositions containing the same |
JP2000565894A JP2002523371A (en) | 1998-08-21 | 1999-08-19 | Compounds, compositions and methods for treating or preventing viral infections and related diseases |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9747698P | 1998-08-21 | 1998-08-21 | |
US60/097,476 | 1998-08-21 | ||
US11321298P | 1998-12-22 | 1998-12-22 | |
US60/113,212 | 1998-12-22 | ||
US11932899P | 1999-02-09 | 1999-02-09 | |
US60/119,328 | 1999-02-09 | ||
US13558699P | 1999-05-24 | 1999-05-24 | |
US13558599P | 1999-05-24 | 1999-05-24 | |
US60/135,586 | 1999-05-24 | ||
US60/135,585 | 1999-05-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09763261 A-371-Of-International | 2001-04-23 | ||
US10/366,796 Continuation US20030195213A1 (en) | 1998-08-21 | 2003-02-14 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000010573A1 true WO2000010573A1 (en) | 2000-03-02 |
Family
ID=27536838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/018785 WO2000010573A1 (en) | 1998-08-21 | 1999-08-19 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1128832A4 (en) |
JP (1) | JP2002523371A (en) |
KR (1) | KR20010099623A (en) |
CN (1) | CN1325309A (en) |
AU (1) | AU743411B2 (en) |
BR (1) | BR9913157A (en) |
CA (1) | CA2341970A1 (en) |
ID (1) | ID27787A (en) |
IL (1) | IL141456A0 (en) |
WO (1) | WO2000010573A1 (en) |
Cited By (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001077091A2 (en) * | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
EP1192143A1 (en) * | 1999-06-10 | 2002-04-03 | Warner-Lambert Company | Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
GB2376944A (en) * | 2001-05-18 | 2002-12-31 | Pantherix Ltd | Polycyclic heterocyclic compounds and their therapeutic use |
WO2003007945A1 (en) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
WO2003043998A1 (en) * | 2001-11-15 | 2003-05-30 | Incyte San Diego Incorporated | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
GB2387172A (en) * | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
WO2003097621A1 (en) * | 2002-05-17 | 2003-11-27 | Qlt Inc. | Methods of using thiazolidinedithione derivatives |
FR2845000A1 (en) * | 2002-09-27 | 2004-04-02 | Oreal | Stimulating hair growth and/or inhibiting hair loss, using new or known 2-(heterocyclylidene-methyl)-5-phenyl-furan, thiophene or pyrrole derivative 15-hydroxy-prostaglandin dehydrogenase inhibitors |
WO2004043955A1 (en) * | 2002-11-13 | 2004-05-27 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
US6765013B2 (en) | 1999-08-31 | 2004-07-20 | Incyte San Diego | Thiazolidinedione derivatives for the treatment of diabetes and other diseases |
JP2004525873A (en) * | 2000-09-29 | 2004-08-26 | ニューロジェン・コーポレーション | High affinity small molecule C5a receptor modulator |
US6803374B2 (en) | 2001-09-26 | 2004-10-12 | Bristol-Myers Squibb Company | Compounds useful for treating hepatitis C virus |
WO2005007141A2 (en) * | 2003-07-11 | 2005-01-27 | Proteologics, Inc. | Ubiquitin ligase inhibitors and methods related thereto |
WO2005020990A1 (en) * | 2003-07-30 | 2005-03-10 | Centre National De La Recherche Scientifique | Antibiotic thiazolidines |
US6869964B2 (en) | 2002-05-20 | 2005-03-22 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis C virus inhibitors |
US6878722B2 (en) | 2002-05-20 | 2005-04-12 | Bristol-Myers Squibb Company | Substituted cycloalkyl P1′ hepatitis C virus inhibitors |
WO2005034850A2 (en) | 2003-09-11 | 2005-04-21 | Bristol-Myers Squibb Company | Cycloalkyl heterocycles for treating hepatitis c virus |
WO2005041951A2 (en) * | 2003-10-28 | 2005-05-12 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives for use as antiviral agents |
US6930106B2 (en) | 2002-07-01 | 2005-08-16 | Pharmacia & Upjohn Company | Inhibitors of HCV NS5B polymerase |
US6995174B2 (en) | 2002-05-20 | 2006-02-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7026339B2 (en) | 2003-11-07 | 2006-04-11 | Fan Yang | Inhibitors of HCV NS5B polymerase |
US7041690B2 (en) | 2002-07-01 | 2006-05-09 | Pharmacia & Upjohn Company, Llc | Inhibitors of HCV NS5B polymerase |
US7041698B2 (en) | 2002-05-20 | 2006-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2006117306A1 (en) | 2005-05-04 | 2006-11-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7141574B2 (en) | 2001-07-25 | 2006-11-28 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US7153875B2 (en) | 2001-03-07 | 2006-12-26 | Incyte San Diego | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
WO2006138118A3 (en) * | 2005-06-15 | 2007-07-26 | New York Blood Ct Inc | Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds |
US7265139B2 (en) | 2001-03-08 | 2007-09-04 | Incyte San Diego Inc. | RXR activating molecules |
WO2007119889A1 (en) | 2006-04-18 | 2007-10-25 | Japan Tobacco Inc. | Novel piperazine compound, and use thereof as hcv polymerase inhibitor |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008043704A1 (en) | 2006-10-10 | 2008-04-17 | Medivir Ab | Hcv nucleoside inhibitor |
EP2033654A1 (en) | 2003-04-16 | 2009-03-11 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
WO2009059243A1 (en) * | 2007-11-01 | 2009-05-07 | The Uab Research Foundation | Treating and preventing viral infections |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
EP2206715A1 (en) | 2004-02-24 | 2010-07-14 | Japan Tobacco, Inc. | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor |
US7879851B2 (en) | 2004-02-20 | 2011-02-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2011058084A1 (en) | 2009-11-14 | 2011-05-19 | F. Hoffmann-La Roche Ag | Biomarkers for predicting rapid response to hcv treatment |
US7947717B2 (en) | 2008-07-18 | 2011-05-24 | Burnham Institute For Medical Research | Inhibitors of lethal factor protease |
WO2011067195A1 (en) | 2009-12-02 | 2011-06-09 | F. Hoffmann-La Roche Ag | Biomarkers for predicting sustained response to hcv treatment |
WO2011075784A1 (en) * | 2009-12-23 | 2011-06-30 | Peter Maccallum Cancer Institute | Compounds, preparations and uses thereof |
US7977331B1 (en) | 2004-02-24 | 2011-07-12 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US8058295B2 (en) | 2002-09-30 | 2011-11-15 | The Regents Of The University Of California | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
US8178491B2 (en) | 2007-06-29 | 2012-05-15 | Gilead Sciences, Inc. | Antiviral compounds |
US8268816B2 (en) * | 2006-12-19 | 2012-09-18 | Vineet Gupta | Compounds for modulating integrin CD11b/CD18 |
WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
WO2012175581A1 (en) | 2011-06-24 | 2012-12-27 | F. Hoffmann-La Roche Ag | Antiviral compounds |
EP2543368A1 (en) | 2007-12-11 | 2013-01-09 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
WO2013053657A1 (en) | 2011-10-10 | 2013-04-18 | F. Hoffmann-La Roche Ag | Antiviral compounds |
WO2013087743A1 (en) | 2011-12-16 | 2013-06-20 | F. Hoffmann-La Roche Ag | Inhibitors of hcv ns5a |
WO2013092481A1 (en) | 2011-12-20 | 2013-06-27 | F. Hoffmann-La Roche Ag | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
WO2013092447A1 (en) | 2011-12-20 | 2013-06-27 | F. Hoffmann-La Roche Ag | 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication |
US8513186B2 (en) | 2007-06-29 | 2013-08-20 | Gilead Sciences, Inc. | Antiviral compounds |
WO2013124335A1 (en) | 2012-02-24 | 2013-08-29 | F. Hoffmann-La Roche Ag | Antiviral compounds |
US8618151B2 (en) | 2008-12-03 | 2013-12-31 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
WO2014006066A1 (en) | 2012-07-06 | 2014-01-09 | F. Hoffmann-La Roche Ag | Triazole compounds as antivirals |
WO2014114573A1 (en) | 2013-01-23 | 2014-07-31 | F. Hoffmann-La Roche Ag | Antiviral triazole derivatives |
EP2774927A1 (en) | 2008-12-03 | 2014-09-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
WO2014135422A1 (en) | 2013-03-05 | 2014-09-12 | F. Hoffmann-La Roche Ag | Antiviral compounds |
WO2014148949A1 (en) | 2013-03-22 | 2014-09-25 | Асави, Ллс | Alkyl 2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2н-pyrimidin-1-yl)-3-hydroxy- tetrahydro-furan-2-yl-methoxy]-phenoxy-phosphoryl-amino}-propionates, nucleoside inhibitors of hcv ns5b rna-polymerase, and methods for producing and use thereof |
US8877707B2 (en) | 2010-05-24 | 2014-11-04 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
WO2014186637A1 (en) | 2013-05-16 | 2014-11-20 | Riboscience Llc | 4'-fluor0-2'-methyl substituted nucleoside derivatives |
US9023876B2 (en) | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
US9150554B2 (en) | 2009-03-27 | 2015-10-06 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
US9249176B2 (en) | 2013-05-16 | 2016-02-02 | Riboscience Llc | 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US9255088B2 (en) | 2010-08-11 | 2016-02-09 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
US9328105B2 (en) | 2012-04-20 | 2016-05-03 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
US9598395B2 (en) | 2012-03-23 | 2017-03-21 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
US10682369B2 (en) | 2017-09-21 | 2020-06-16 | Riboscience Llc | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US10821101B2 (en) * | 2018-05-16 | 2020-11-03 | Avixgen Inc. | Pharmaceutical composition for preventing or treating AIDS comprising rhodanine derivative |
US10953030B2 (en) | 2013-05-16 | 2021-03-23 | Riboscience Llc | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
WO2023161427A1 (en) | 2022-02-24 | 2023-08-31 | Eisbach Bio Gmbh | Viral combination therapy |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL376147A1 (en) * | 2002-09-30 | 2005-12-27 | The Regents Of The University Of California | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
EP2019830A4 (en) * | 2006-05-04 | 2011-01-19 | Inst Hepatitis & Virus Res | Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus |
KR101159000B1 (en) * | 2010-06-18 | 2012-06-21 | (주) 에빅스젠 | Novel rhodanine derivative, process for preparing the same and pharmaceutical composition for preventing or treating AIDS comprising the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909467A (en) * | 1958-07-09 | 1959-10-20 | Us Vitamin Pharm Corp | 3-(d-alpha-methylphenethyl)-5-methyl-1, 3-oxazolidine-2, 4-dione |
US3888984A (en) * | 1972-03-13 | 1975-06-10 | Lilly Industries Ltd | Oxazole and imidazole derivatives as antifungal agents |
US4367234A (en) * | 1980-07-28 | 1983-01-04 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4387101A (en) * | 1980-01-24 | 1983-06-07 | Takeda Chemical Industries, Ltd. | Thiazolidine derivatives and their use |
US5693337A (en) * | 1994-07-13 | 1997-12-02 | Wakamoto Pharmaceutical Co., Ltd. | Stable lipid emulsion |
US5834466A (en) * | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021934A1 (en) * | 1992-05-01 | 1993-11-11 | Commonwealth Scientific And Industrial Research Organisation | Heteropolytungstates in the treatment of flavivirus infections |
DE19645974C1 (en) * | 1996-11-07 | 1998-08-13 | Andreas Johannes Kesel | (Z) -5 - [[3-Hydroxy-2-methyl-5 - [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone, process for its preparation and use |
-
1999
- 1999-08-19 EP EP99942288A patent/EP1128832A4/en not_active Withdrawn
- 1999-08-19 KR KR1020017002117A patent/KR20010099623A/en not_active Application Discontinuation
- 1999-08-19 IL IL14145699A patent/IL141456A0/en unknown
- 1999-08-19 ID IDW20010428A patent/ID27787A/en unknown
- 1999-08-19 AU AU55702/99A patent/AU743411B2/en not_active Ceased
- 1999-08-19 JP JP2000565894A patent/JP2002523371A/en active Pending
- 1999-08-19 CA CA002341970A patent/CA2341970A1/en not_active Abandoned
- 1999-08-19 CN CN99812282A patent/CN1325309A/en active Pending
- 1999-08-19 WO PCT/US1999/018785 patent/WO2000010573A1/en not_active Application Discontinuation
- 1999-08-19 BR BR9913157-9A patent/BR9913157A/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909467A (en) * | 1958-07-09 | 1959-10-20 | Us Vitamin Pharm Corp | 3-(d-alpha-methylphenethyl)-5-methyl-1, 3-oxazolidine-2, 4-dione |
US3888984A (en) * | 1972-03-13 | 1975-06-10 | Lilly Industries Ltd | Oxazole and imidazole derivatives as antifungal agents |
US4387101A (en) * | 1980-01-24 | 1983-06-07 | Takeda Chemical Industries, Ltd. | Thiazolidine derivatives and their use |
US4367234A (en) * | 1980-07-28 | 1983-01-04 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US5693337A (en) * | 1994-07-13 | 1997-12-02 | Wakamoto Pharmaceutical Co., Ltd. | Stable lipid emulsion |
US5834466A (en) * | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
Non-Patent Citations (1)
Title |
---|
See also references of EP1128832A4 * |
Cited By (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1192143A1 (en) * | 1999-06-10 | 2002-04-03 | Warner-Lambert Company | Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
US6765013B2 (en) | 1999-08-31 | 2004-07-20 | Incyte San Diego | Thiazolidinedione derivatives for the treatment of diabetes and other diseases |
US7226940B2 (en) | 1999-08-31 | 2007-06-05 | Incyte San Diego, Inc. | Substituted heterocycles for the treatment of diabetes and other diseases |
US6974826B2 (en) | 1999-08-31 | 2005-12-13 | Incyte San Diego Inc. | Imidazolidinedione derivatives for the treatment of diabetes and other diseases |
WO2001077091A2 (en) * | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
WO2001077091A3 (en) * | 2000-04-05 | 2002-03-21 | Tularik Inc | Ns5b hcv polymerase inhibitors |
US6727267B2 (en) | 2000-04-05 | 2004-04-27 | Tularik Inc. | NS5B HVC polymerase inhibitors |
US6479508B1 (en) | 2000-07-06 | 2002-11-12 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US7439258B2 (en) | 2000-07-06 | 2008-10-21 | Boehringer Ingelheim (Canada) Ltd | Viral polymerase inhibitors |
US6794404B2 (en) | 2000-07-06 | 2004-09-21 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
JP2004525873A (en) * | 2000-09-29 | 2004-08-26 | ニューロジェン・コーポレーション | High affinity small molecule C5a receptor modulator |
US7153875B2 (en) | 2001-03-07 | 2006-12-26 | Incyte San Diego | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
US7265139B2 (en) | 2001-03-08 | 2007-09-04 | Incyte San Diego Inc. | RXR activating molecules |
GB2376944A (en) * | 2001-05-18 | 2002-12-31 | Pantherix Ltd | Polycyclic heterocyclic compounds and their therapeutic use |
WO2003007945A1 (en) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
US7157486B2 (en) | 2001-07-25 | 2007-01-02 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
EP1891951A1 (en) | 2001-07-25 | 2008-02-27 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US7141574B2 (en) | 2001-07-25 | 2006-11-28 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US7803944B2 (en) | 2001-07-25 | 2010-09-28 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
US6803374B2 (en) | 2001-09-26 | 2004-10-12 | Bristol-Myers Squibb Company | Compounds useful for treating hepatitis C virus |
WO2003043998A1 (en) * | 2001-11-15 | 2003-05-30 | Incyte San Diego Incorporated | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
US7071218B2 (en) | 2001-11-15 | 2006-07-04 | Incyte San Diego Incorporated | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases |
US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
GB2387172A (en) * | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
WO2003097621A1 (en) * | 2002-05-17 | 2003-11-27 | Qlt Inc. | Methods of using thiazolidinedithione derivatives |
US6878722B2 (en) | 2002-05-20 | 2005-04-12 | Bristol-Myers Squibb Company | Substituted cycloalkyl P1′ hepatitis C virus inhibitors |
US6869964B2 (en) | 2002-05-20 | 2005-03-22 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis C virus inhibitors |
US7041698B2 (en) | 2002-05-20 | 2006-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US6995174B2 (en) | 2002-05-20 | 2006-02-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US6930106B2 (en) | 2002-07-01 | 2005-08-16 | Pharmacia & Upjohn Company | Inhibitors of HCV NS5B polymerase |
US7041690B2 (en) | 2002-07-01 | 2006-05-09 | Pharmacia & Upjohn Company, Llc | Inhibitors of HCV NS5B polymerase |
FR2845000A1 (en) * | 2002-09-27 | 2004-04-02 | Oreal | Stimulating hair growth and/or inhibiting hair loss, using new or known 2-(heterocyclylidene-methyl)-5-phenyl-furan, thiophene or pyrrole derivative 15-hydroxy-prostaglandin dehydrogenase inhibitors |
WO2004028441A2 (en) * | 2002-09-27 | 2004-04-08 | L'oreal | Heterocyclic compound for stimulating or inducing hair or eyelash growth and/or for slowing down hair loss, composition containing same, and uses thereof |
WO2004028441A3 (en) * | 2002-09-27 | 2004-05-06 | Oreal | Heterocyclic compound for stimulating or inducing hair or eyelash growth and/or for slowing down hair loss, composition containing same, and uses thereof |
US7294641B2 (en) | 2002-09-27 | 2007-11-13 | L'oreal | Heterocyclic compound for stimulating or inducing the growth of the hair or eyelashes and/or slowing down their loss, composition comprising it and its uses |
US8058295B2 (en) | 2002-09-30 | 2011-11-15 | The Regents Of The University Of California | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
WO2004043955A1 (en) * | 2002-11-13 | 2004-05-27 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
EP2033654A1 (en) | 2003-04-16 | 2009-03-11 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
WO2005007141A3 (en) * | 2003-07-11 | 2005-03-24 | Proteologics Inc | Ubiquitin ligase inhibitors and methods related thereto |
WO2005007141A2 (en) * | 2003-07-11 | 2005-01-27 | Proteologics, Inc. | Ubiquitin ligase inhibitors and methods related thereto |
US7659277B2 (en) | 2003-07-11 | 2010-02-09 | Proteologies, Ltd. | Ubiquitin ligase inhibitors and methods related thereto |
WO2005020990A1 (en) * | 2003-07-30 | 2005-03-10 | Centre National De La Recherche Scientifique | Antibiotic thiazolidines |
US7112601B2 (en) | 2003-09-11 | 2006-09-26 | Bristol-Myers Squibb Company | Cycloalkyl heterocycles for treating hepatitis C virus |
WO2005034850A2 (en) | 2003-09-11 | 2005-04-21 | Bristol-Myers Squibb Company | Cycloalkyl heterocycles for treating hepatitis c virus |
US7566732B2 (en) | 2003-10-28 | 2009-07-28 | Rigel Pharmaceuticals, Inc. | Rhodanine compositions for use as antiviral agents |
WO2005041951A3 (en) * | 2003-10-28 | 2005-10-06 | Rigel Pharmaceuticals Inc | Rhodanine derivatives for use as antiviral agents |
WO2005041951A2 (en) * | 2003-10-28 | 2005-05-12 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives for use as antiviral agents |
US7026339B2 (en) | 2003-11-07 | 2006-04-11 | Fan Yang | Inhibitors of HCV NS5B polymerase |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8030309B2 (en) | 2004-02-20 | 2011-10-04 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7879851B2 (en) | 2004-02-20 | 2011-02-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7977331B1 (en) | 2004-02-24 | 2011-07-12 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
EP2206715A1 (en) | 2004-02-24 | 2010-07-14 | Japan Tobacco, Inc. | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
WO2006117306A1 (en) | 2005-05-04 | 2006-11-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
WO2006138118A3 (en) * | 2005-06-15 | 2007-07-26 | New York Blood Ct Inc | Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds |
WO2007119889A1 (en) | 2006-04-18 | 2007-10-25 | Japan Tobacco Inc. | Novel piperazine compound, and use thereof as hcv polymerase inhibitor |
WO2008043704A1 (en) | 2006-10-10 | 2008-04-17 | Medivir Ab | Hcv nucleoside inhibitor |
EP2361922A1 (en) | 2006-10-10 | 2011-08-31 | Medivir AB | Intermediate to HCV-Nucleoside Inhibitors |
US10408820B2 (en) | 2006-12-19 | 2019-09-10 | The General Hospital Corporation | Compounds for modulating integrin CD11B/CD18 |
US8268816B2 (en) * | 2006-12-19 | 2012-09-18 | Vineet Gupta | Compounds for modulating integrin CD11b/CD18 |
US8809266B2 (en) | 2007-06-29 | 2014-08-19 | Gilead Sciences, Inc. | Antiviral compounds |
US8809267B2 (en) | 2007-06-29 | 2014-08-19 | Gilead Sciences, Inc. | Antiviral compounds |
US8178491B2 (en) | 2007-06-29 | 2012-05-15 | Gilead Sciences, Inc. | Antiviral compounds |
US8513186B2 (en) | 2007-06-29 | 2013-08-20 | Gilead Sciences, Inc. | Antiviral compounds |
US8466177B2 (en) | 2007-11-01 | 2013-06-18 | The Uab Research Foundation | Treating and preventing viral infections |
WO2009059243A1 (en) * | 2007-11-01 | 2009-05-07 | The Uab Research Foundation | Treating and preventing viral infections |
EP2543368A1 (en) | 2007-12-11 | 2013-01-09 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
US7947717B2 (en) | 2008-07-18 | 2011-05-24 | Burnham Institute For Medical Research | Inhibitors of lethal factor protease |
EP2774927A1 (en) | 2008-12-03 | 2014-09-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
US8618151B2 (en) | 2008-12-03 | 2013-12-31 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
EP2682393A1 (en) | 2008-12-03 | 2014-01-08 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A comprising a bicyclic core. |
US8865756B2 (en) | 2008-12-03 | 2014-10-21 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
US9150554B2 (en) | 2009-03-27 | 2015-10-06 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
WO2011058084A1 (en) | 2009-11-14 | 2011-05-19 | F. Hoffmann-La Roche Ag | Biomarkers for predicting rapid response to hcv treatment |
WO2011067195A1 (en) | 2009-12-02 | 2011-06-09 | F. Hoffmann-La Roche Ag | Biomarkers for predicting sustained response to hcv treatment |
WO2011075784A1 (en) * | 2009-12-23 | 2011-06-30 | Peter Maccallum Cancer Institute | Compounds, preparations and uses thereof |
US8877707B2 (en) | 2010-05-24 | 2014-11-04 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
US9023876B2 (en) | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
US9255088B2 (en) | 2010-08-11 | 2016-02-09 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
WO2012175581A1 (en) | 2011-06-24 | 2012-12-27 | F. Hoffmann-La Roche Ag | Antiviral compounds |
WO2013053657A1 (en) | 2011-10-10 | 2013-04-18 | F. Hoffmann-La Roche Ag | Antiviral compounds |
WO2013087743A1 (en) | 2011-12-16 | 2013-06-20 | F. Hoffmann-La Roche Ag | Inhibitors of hcv ns5a |
WO2013092481A1 (en) | 2011-12-20 | 2013-06-27 | F. Hoffmann-La Roche Ag | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
US9708357B2 (en) | 2011-12-20 | 2017-07-18 | Riboscience, LLC | 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication |
WO2013092447A1 (en) | 2011-12-20 | 2013-06-27 | F. Hoffmann-La Roche Ag | 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication |
US9108999B2 (en) | 2011-12-20 | 2015-08-18 | Riboscience Llc | 2′, 4′-difluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
WO2013124335A1 (en) | 2012-02-24 | 2013-08-29 | F. Hoffmann-La Roche Ag | Antiviral compounds |
US9598395B2 (en) | 2012-03-23 | 2017-03-21 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
US10239871B2 (en) | 2012-04-20 | 2019-03-26 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
US9328105B2 (en) | 2012-04-20 | 2016-05-03 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
WO2014006066A1 (en) | 2012-07-06 | 2014-01-09 | F. Hoffmann-La Roche Ag | Triazole compounds as antivirals |
WO2014114573A1 (en) | 2013-01-23 | 2014-07-31 | F. Hoffmann-La Roche Ag | Antiviral triazole derivatives |
WO2014135422A1 (en) | 2013-03-05 | 2014-09-12 | F. Hoffmann-La Roche Ag | Antiviral compounds |
WO2014148949A1 (en) | 2013-03-22 | 2014-09-25 | Асави, Ллс | Alkyl 2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2н-pyrimidin-1-yl)-3-hydroxy- tetrahydro-furan-2-yl-methoxy]-phenoxy-phosphoryl-amino}-propionates, nucleoside inhibitors of hcv ns5b rna-polymerase, and methods for producing and use thereof |
US9694028B2 (en) | 2013-05-16 | 2017-07-04 | Riboscience Llc | 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US9895442B2 (en) | 2013-05-16 | 2018-02-20 | Riboscience Llc | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US9249176B2 (en) | 2013-05-16 | 2016-02-02 | Riboscience Llc | 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication |
WO2014186637A1 (en) | 2013-05-16 | 2014-11-20 | Riboscience Llc | 4'-fluor0-2'-methyl substituted nucleoside derivatives |
US10953030B2 (en) | 2013-05-16 | 2021-03-23 | Riboscience Llc | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US10682369B2 (en) | 2017-09-21 | 2020-06-16 | Riboscience Llc | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US11351186B2 (en) | 2017-09-21 | 2022-06-07 | Riboscience Llc | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US10821101B2 (en) * | 2018-05-16 | 2020-11-03 | Avixgen Inc. | Pharmaceutical composition for preventing or treating AIDS comprising rhodanine derivative |
US11141407B2 (en) | 2018-05-16 | 2021-10-12 | Avixgen Inc. | Pharmaceutical composition for preventing or treating aids comprising rhodanine derivative |
WO2023161427A1 (en) | 2022-02-24 | 2023-08-31 | Eisbach Bio Gmbh | Viral combination therapy |
Also Published As
Publication number | Publication date |
---|---|
AU743411B2 (en) | 2002-01-24 |
KR20010099623A (en) | 2001-11-09 |
JP2002523371A (en) | 2002-07-30 |
CN1325309A (en) | 2001-12-05 |
EP1128832A4 (en) | 2003-03-05 |
ID27787A (en) | 2001-04-26 |
AU5570299A (en) | 2000-03-14 |
BR9913157A (en) | 2001-05-15 |
CA2341970A1 (en) | 2000-03-02 |
EP1128832A1 (en) | 2001-09-05 |
IL141456A0 (en) | 2002-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU743411B2 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
US6316492B1 (en) | Methods for treating or preventing viral infections and associated diseases | |
AU751201B2 (en) | Methods for treating or preventing viral infections and associated diseases | |
CN101657443B (en) | [1,2,3] triazolyl substituted quinolines and coumarins as inhibitors of leukotriene biosynthesis | |
US20020052396A1 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
US4882342A (en) | 5-alkylbenzimidazoles, method of use and pharmaceutical compositions | |
JP2008506762A (en) | Imidazole and thiazole derivatives as antiviral agents | |
CN101535303A (en) | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level | |
US20040248950A1 (en) | Apo ai expression accelerating agent | |
EP0780389A1 (en) | Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them | |
ZA200005577B (en) | Substituted indolealkanoic acids. | |
AU596969B2 (en) | 2,5 - diaryl tetrahydrofurans and 2-aryl-5-cyclo tetrahydrofurans and analogs thereof as paf antogonists | |
WO2007143597A2 (en) | Organic compounds | |
JP2004521915A (en) | Pyrazole derivatives for TGF overexpression | |
WO2009137493A1 (en) | 2-substituted benzofuran compounds to treat infection with hepatitis c virus | |
US20040198741A1 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
NZ227287A (en) | 2,5-diaryl tetrahydrofurans and medicaments | |
EP0365089A3 (en) | 2-aryl-5(3-methoxy-5-(hydroxypropylsulfonyl)-4-propoxyphenyl) tetrahydrothiophen and analogs | |
CN101018785A (en) | Thiazolinone 2-substituted quinolines | |
JP2001114779A (en) | 5-pyridyl-1-azole compound, method for producing the same and use thereof | |
MXPA01003030A (en) | Methods for treating or preventing viral infections and associated diseases | |
JP2005035998A (en) | Bislactone derivative and use of the same as pharmaceutical composition | |
JP2006273847A (en) | Cinnamoyl compound and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99812282.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 55702/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 509898 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 141456 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017002117 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2341970 Country of ref document: CA Ref document number: 2341970 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/00577 Country of ref document: TR Ref document number: PA/A/2001/001874 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200100227 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999942288 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09763261 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999942288 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017002117 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 55702/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017002117 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999942288 Country of ref document: EP |